1 June 2009
Chairman and chief executive of Ranbaxy Laboratories, Malvinder Singh, has stepped down, handing more control over the generic drug maker to its Japanese owner Daiichi Sankyo.
Mr Singh's family founded the company and it has since become one of India's best-known multinational companies. He will be replaced as chief executive by Atul Sobti, currently the company's chief operating officer and Tsutomo Une, Daiichi's senior executive officer, will take over his responsibilities as chairman.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.